{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:54:59Z","timestamp":1793829299248,"version":"4.6.1"},"reference-count":107,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T00:00:00Z","timestamp":1716768000000},"content-version":"vor","delay-in-days":147,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Research in Microbial Sciences"],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/j.crmicr.2024.100245","type":"journal-article","created":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T12:51:31Z","timestamp":1716814291000},"page":"100245","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Ibrexafungerp: A narrative overview"],"prefix":"10.1016","volume":"6","author":[{"given":"L'Emir Wassim","family":"El Ayoubi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Allaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elie","family":"Moussa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6413-3396","authenticated-orcid":false,"given":"Souha S.","family":"Kanj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.crmicr.2024.100245_bib0001","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1128\/CMR.00076-09","article-title":"Candida infections of the genitourinary tract","volume":"23","author":"Achkar","year":"2010","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.crmicr.2024.100245_bib0002","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms9040807","article-title":"Candida auris: epidemiology, diagnosis, pathogenesis, antifungal susceptibility, and infection control measures to combat the spread of infections in healthcare facilities","volume":"9","author":"Ahmad","year":"2021","journal-title":"Microorganisms"},{"key":"10.1016\/j.crmicr.2024.100245_bib0003","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1164\/rccm.202306-1022ED","article-title":"Viral-associated pulmonary aspergillosis: have we finally overcome the debate of colonization versus infection?","volume":"208","author":"Albrich","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.crmicr.2024.100245_bib0004","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01324-23","article-title":"In vitro activity of ibrexafungerp against clinically relevant echinocandin-resistant Candida strains","volume":"68","author":"Aldejohann","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.crmicr.2024.100245_bib0005","doi-asserted-by":"crossref","first-page":"S642","DOI":"10.1093\/ofid\/ofaa439.1432","article-title":"Efficacy and safety of oral ibrexafungerp in 41 patients with refractory fungal diseases, interim analysis of a phase 3 open-label study (FURI)","volume":"7","author":"Alexander","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.crmicr.2024.100245_bib0006","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1093\/cid\/cit136","article-title":"Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations","volume":"56","author":"Alexander","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.crmicr.2024.100245_bib0007","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.3390\/jof8111121","article-title":"Ibrexafungerp, a novel triterpenoid antifungal in development for the treatment of mold infections","volume":"8","author":"Angulo","year":"2022","journal-title":"J. Fungi (Basel)"},{"key":"10.1016\/j.crmicr.2024.100245_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127661","article-title":"Ibrexafungerp: an orally active beta-1,3-glucan synthesis inhibitor","volume":"32","author":"Apgar","year":"2021","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.crmicr.2024.100245_bib0009","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02136-19","article-title":"In vitro activity of ibrexafungerp (SCY-078) against Candida auris isolates as determined by EUCAST methodology and comparison with activity against C. albicans and C. glabrata and with the activities of six comparator agents","volume":"64","author":"Arendrup","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.crmicr.2024.100245_bib0010","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.01564-17","article-title":"Update from a 12-year nationwide Fungemia surveillance: increasing intrinsic and acquired resistance causes concern","volume":"56","author":"Astvad","year":"2018","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.crmicr.2024.100245_bib0011","series-title":"European Congress of Clinical Microbiology and Infectious Diseases","article-title":"Efficacy of ibrexafungerp (formerly SCY-078) against pneumocystis pneumonia in a murine therapeutic model","author":"Barat","year":"2019"},{"key":"10.1016\/j.crmicr.2024.100245_bib0012","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1093\/cid\/ciy776","article-title":"Estimation of direct healthcare costs of fungal diseases in the United States","volume":"68","author":"Benedict","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.crmicr.2024.100245_bib0013","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00435-17","article-title":"In vitro activity of a novel glucan synthase inhibitor, SCY-078, against clinical isolates of Candida auris","volume":"61","author":"Berkow","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.crmicr.2024.100245_bib0014","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3390\/jof3040057","article-title":"Global and multi-national prevalence of fungal diseases-estimate precision","volume":"3","author":"Bongomin","year":"2017","journal-title":"J. Fungi (Basel)"},{"key":"10.1016\/j.crmicr.2024.100245_bib0015","doi-asserted-by":"crossref","first-page":"S643","DOI":"10.1093\/ofid\/ofaa439.1435","article-title":"Prevention of pneumocystis pneumonia by ibrexafungerp in a murine prophylaxis model","volume":"7","author":"Borroto-Esoda","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.crmicr.2024.100245_bib0016","doi-asserted-by":"crossref","first-page":"S472","DOI":"10.1093\/ofid\/ofx163.1207","article-title":"SCY-078 demonstrates significant antifungal activity in a murine model of invasive aspergillosis","volume":"4","author":"Borroto-Esoda","year":"2017","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.crmicr.2024.100245_bib0017","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01397-19","article-title":"On the emergence of Candida auris: climate change, azoles, swamps, and birds","volume":"10","author":"Casadevall","year":"2019","journal-title":"mBio"},{"key":"10.1016\/j.crmicr.2024.100245_bib0018","unstructured":"CDC. 2022a. 'Learn more about vaginal candidiasis (vaginal yeast infections', Accessed November 10 2023. https:\/\/www.cdc.gov\/fungal\/diseases\/candidiasis\/genital\/index.html."},{"key":"10.1016\/j.crmicr.2024.100245_bib0019","unstructured":"CDC. 2022b. \u2018COVID-19 U.S. IMPACT ON ANTIMICROBIAL RESISTANCE\u2019. Accessed April 1 2024. https:\/\/www.cdc.gov\/drugresistance\/pdf\/covid19-impact-report-508.pdf."},{"key":"10.1016\/j.crmicr.2024.100245_bib0020","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2165\/11585270-000000000-00000","article-title":"Echinocandin antifungal drugs in fungal infections: a comparison","volume":"71","author":"Chen","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.crmicr.2024.100245_bib0021","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006290","article-title":"Candida auris: a rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally","volume":"13","author":"Chowdhary","year":"2017","journal-title":"PLoS. Pathog."},{"key":"10.1016\/j.crmicr.2024.100245_bib0022","unstructured":"ClinicalTrials.gov. 2017a. 'Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida auris (CARES) (CARES)', Accessed November 10 2023. https:\/\/clinicaltrials.gov\/study\/NCT03363841."},{"key":"10.1016\/j.crmicr.2024.100245_bib0023","unstructured":"ClinicalTrials.gov. 2017b. 'Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment (FURI)', Accessed November 10 2023. https:\/\/clinicaltrials.gov\/study\/NCT03059992."},{"key":"10.1016\/j.crmicr.2024.100245_bib0024","unstructured":"ClinicalTrials.gov. 2019a. 'Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC) (CANDLE)', Accessed November 10 2023. https:\/\/clinicaltrials.gov\/study\/NCT04029116."},{"key":"10.1016\/j.crmicr.2024.100245_bib0025","unstructured":"ClinicalTrials.gov. 2019b. 'Study to Evaluate the Safety and Efficacy of the Coadministration of Ibrexafungerp (SCY-078) With Voriconazole in Patients With Invasive Pulmonary Aspergillosis (SCYNERGIA)', Accessed November 10 2023. https:\/\/clinicaltrials.gov\/study\/NCT03672292?intr=NCT03672292&rank=1."},{"key":"10.1016\/j.crmicr.2024.100245_bib0026","unstructured":"ClinicalTrials.gov. 2022a. 'Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis', Accessed November 10 2023. https:\/\/clinicaltrials.gov\/study\/NCT05399641."},{"key":"10.1016\/j.crmicr.2024.100245_bib0027","unstructured":"ClinicalTrials.gov. 2022b. 'Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole (MARIO)', Accessed November 10 2023. https:\/\/clinicaltrials.gov\/study\/NCT05178862."},{"key":"10.1016\/j.crmicr.2024.100245_bib0028","unstructured":"ClinicalTrials.gov. 2023. \u2018Safety of Pregnant Subjects Exposed to Ibrexafungerp Including Infant Outcomes\u2019, Accessed April 1 2024. https:\/\/clinicaltrials.gov\/study\/NCT05908682."},{"key":"10.1016\/j.crmicr.2024.100245_bib0029","series-title":"European Congress of Clinical Microbiology and Infectious Diseases","article-title":"Outcomes of oral ibrexafungerp in 33 patients with refractory fungal diseases, interim analysis of a phase III open-label study (FURI) 06. Fungal infection & disease","author":"Cornely","year":"2021"},{"key":"10.1016\/j.crmicr.2024.100245_bib0030","series-title":"European Congress of Clinical Microbiology and Infectious Diseases","article-title":"Favorable response to oral ibrexafungerp (formerly SCY-078) in patients with refractory fungal diseases, interim analysis by pathogen from a phase 3 open-label study (FURI)","author":"Cornely","year":"2019"},{"key":"10.1016\/j.crmicr.2024.100245_bib0031","doi-asserted-by":"crossref","first-page":"440","DOI":"10.3390\/jof8050440","article-title":"The feasibility of ibrexafungerp for the treatment of fungal infections in patients with hematological malignancies","volume":"8","author":"Daraskevicius","year":"2022","journal-title":"J. Fungi (Basel)"},{"key":"10.1016\/j.crmicr.2024.100245_bib0032","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/mmy\/myz083","article-title":"Ibrexafungerp: a novel oral glucan synthase inhibitor","volume":"58","author":"Davis","year":"2020","journal-title":"Med. Mycol."},{"key":"10.1016\/j.crmicr.2024.100245_bib0033","doi-asserted-by":"crossref","first-page":"e339","DOI":"10.1016\/S1473-3099(18)30103-8","article-title":"Global burden of recurrent vulvovaginal candidiasis: a systematic review","volume":"18","author":"Denning","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.crmicr.2024.100245_bib0034","unstructured":"EMA. 2021. 'EU\/3\/21\/2525: orphan designation for the treatment of invasive candidiasis', Accessed November 10 2023. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/orphan-designations\/eu-3-21-2525."},{"key":"10.1016\/j.crmicr.2024.100245_bib0035","unstructured":"FDA. 2021. \u2018BREXAFEMME\u00ae (ibrexafungerp tablets), for oral use\u2019, Accessed April 1 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/214900s000lbl.pdf."},{"key":"10.1016\/j.crmicr.2024.100245_bib107","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s10096-006-0159-2","article-title":"Attributable mortality of candidemia: a systematic review of matched cohort and case\u2013control studies","volume":"25","author":"Falagas","year":"2006","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.crmicr.2024.100245_bib0036","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.3389\/fmicb.2019.02993","article-title":"The fungal cell wall: Candida, Cryptococcus, and Aspergillus species","volume":"10","author":"Garcia-Rubio","year":"2019","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.crmicr.2024.100245_bib0037","series-title":"European Congress of Clinical Microbiology and Infectious Diseases","article-title":"Efficacy assessment of ibrexafungerp in the neutropenic mouse model of pulmonary mucormycosis","author":"Gebremariam","year":"2022"},{"key":"10.1016\/j.crmicr.2024.100245_bib0038","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3390\/antibiotics9090539","article-title":"Ibrexafungerp: a novel oral triterpenoid antifungal in development for the treatment of Candida auris infections","volume":"9","author":"Ghannoum","year":"2020","journal-title":"Antibiotics. (Basel)"},{"key":"10.1016\/j.crmicr.2024.100245_bib0039","doi-asserted-by":"crossref","first-page":"e00854-20","DOI":"10.1128\/AAC.00854-20","article-title":"Efficacy of ibrexafungerp (SCY-078) against Candida auris in an in vivo guinea pig cutaneous infection model","volume":"64","author":"Ghannoum","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.crmicr.2024.100245_bib0040","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00244-18","article-title":"Evaluation of the antifungal activity of the novel oral glucan synthase inhibitor SCY-078, singly and in combination, for the treatment of invasive aspergillosis","volume":"62","author":"Ghannoum","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.crmicr.2024.100245_bib0041","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1089\/jwh.2022.0132","article-title":"Oral ibrexafungerp for vulvovaginal candidiasis treatment: an analysis of VANISH 303 and VANISH 306","volume":"32","author":"Goje","year":"2023","journal-title":"J. Womens Health (Larchmt)"},{"key":"10.1016\/j.crmicr.2024.100245_bib0042","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s40265-021-01611-0","article-title":"The antifungal pipeline: fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin","volume":"8","author":"Hoenigl","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.crmicr.2024.100245_bib0043","article-title":"Ibrexafungerp: a first-in-class oral triterpenoid glucan synthase inhibitor","volume":"7","author":"Jallow","year":"2021","journal-title":"J. Fungi (Basel)"},{"key":"10.1016\/j.crmicr.2024.100245_bib0044","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1128\/AAC.02145-13","article-title":"Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant Candida species and Aspergillus species isolates","volume":"58","author":"Jimenez-Ortigosa","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.crmicr.2024.100245_bib0045","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00833-17","article-title":"De novo acquisition of resistance to SCY-078 in Candida glabrata involves FKS mutations that both overlap and are distinct from those conferring echinocandin resistance","volume":"61","author":"Jimenez-Ortigosa","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.crmicr.2024.100245_bib0046","series-title":"European Congress of Clinical Microbiology and Infectious Disease","article-title":"Outcomes of oral ibrexafungerp in the treatment of ten patients with Candida auris infections, from the CARES Study","author":"Juneja","year":"2021"},{"key":"10.1016\/j.crmicr.2024.100245_bib0047","article-title":"The battle against fungi: lessons in antifungal stewardship from COVID-19 times","volume":"62","author":"Kanj","year":"2023","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.crmicr.2024.100245_bib0048","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1016\/j.jiph.2019.05.007","article-title":"Epidemiology and burden of invasive fungal infections in the countries of the Arab League","volume":"13","author":"Kmeid","year":"2020","journal-title":"J. Infect. Public Health"},{"key":"10.1016\/j.crmicr.2024.100245_bib0049","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00238-18","article-title":"Understanding echinocandin resistance in the emerging pathogen Candida auris","volume":"62","author":"Kordalewska","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.crmicr.2024.100245_bib0050","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1136\/thoraxjnl-2014-206291","article-title":"The clinical spectrum of pulmonary aspergillosis","volume":"70","author":"Kosmidis","year":"2015","journal-title":"Thorax."},{"key":"10.1016\/j.crmicr.2024.100245_bib0051","doi-asserted-by":"crossref","first-page":"4308","DOI":"10.1128\/AAC.00234-15","article-title":"Antifungal activities of SCY-078 (MK-3118) and standard antifungal agents against clinical non-Aspergillus mold isolates","volume":"59","author":"Lamoth","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.crmicr.2024.100245_bib0052","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02396-16","article-title":"The emerging pathogen Candida auris: growth phenotype, virulence factors, activity of antifungals, and effect of SCY-078, a novel glucan synthesis inhibitor, on growth morphology and biofilm formation","volume":"61","author":"Larkin","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.crmicr.2024.100245_bib0053","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02268-19","article-title":"Penetration of ibrexafungerp (formerly SCY-078) at the site of infection in an intra-abdominal candidiasis mouse model","volume":"64","author":"Lee","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.crmicr.2024.100245_bib0054","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1128\/AAC.04445-14","article-title":"Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model","volume":"59","author":"Lepak","year":"2015","journal-title":"Antimicrob. Agents Chemother"},{"key":"10.1016\/j.crmicr.2024.100245_bib0055","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/s41579-023-00960-9","article-title":"The rapid emergence of antifungal-resistant human-pathogenic fungi","volume":"21","author":"Lockhart","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.crmicr.2024.100245_bib0056","series-title":"European Congress of Clinical Microbiology and Infectious Diseases","article-title":"Evaluate the effect of ibrexafungerp alone and in combination with amphotericin B or posaconazole against Mucor strains using time-kill kinetics and scanning electron microscopy","author":"Long","year":"2023"},{"key":"10.1016\/j.crmicr.2024.100245_bib0057","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1093\/jac\/dkx010","article-title":"The novel oral glucan synthase inhibitor SCY-078 shows in vitro activity against sessile and planktonic Candida spp","volume":"72","author":"Marcos-Zambrano","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.crmicr.2024.100245_bib0058","doi-asserted-by":"crossref","first-page":"1154.e5","DOI":"10.1016\/j.cmi.2022.04.003","article-title":"DeltaF659 and F659S substitutions at the HS1 of FKS2 gene, along with E655A and W715L upstream and downstream substitutions, correlate with high ibrexafungerp MICs against Candida glabrata","volume":"28","author":"Mesquida","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.crmicr.2024.100245_bib0059","series-title":"ASM Microbe","article-title":"CYP-mediated drug interaction profile of SCY-078, a novel glucan synthase inhibitor (GSI)","author":"Murphy","year":"2017"},{"key":"10.1016\/j.crmicr.2024.100245_bib0060","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.mmcr.2016.03.004","article-title":"Two echinocandin-resistant Candida glabrata FKS mutants from South Africa","volume":"11","author":"Naicker","year":"2016","journal-title":"Med. Mycol. Case Rep."},{"key":"10.1016\/j.crmicr.2024.100245_bib0061","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01692-19","article-title":"In vitro activity of ibrexafungerp, a novel glucan synthase inhibitor against Candida glabrata isolates with FKS mutations","volume":"63","author":"Nunnally","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.crmicr.2024.100245_bib0062","doi-asserted-by":"crossref","first-page":"S162","DOI":"10.1093\/cid\/ciab1057","article-title":"Vulvovaginal candidiasis: a review of the evidence for the 2021 centers for disease control and prevention of sexually transmitted infections treatment guidelines","volume":"74","author":"Nyirjesy","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.crmicr.2024.100245_bib0063","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/cid\/ciab841","article-title":"Phase 2 randomized study of oral ibrexafungerp versus fluconazole in vulvovaginal candidiasis","volume":"74","author":"Nyirjesy","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.crmicr.2024.100245_bib0064","unstructured":"OB\/GYN, Contemporary. 2022. 'FDA approves ibrexafungerp for reduction in the incidence of RVVC'. https:\/\/www.contemporaryobgyn.net\/view\/fda-approves-ibrexafungerp-for-reduction-in-the-incidence-of-rvvc."},{"key":"10.1016\/j.crmicr.2024.100245_bib0065","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0966-842X(03)00117-3","article-title":"Antifungal agents: mechanisms of action","volume":"11","author":"Odds","year":"2003","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.crmicr.2024.100245_bib0066","first-page":"323","article-title":"Candida auris: the new fungal threat","volume":"31","author":"Pallotta","year":"2023","journal-title":"Infez. Med."},{"key":"10.1016\/j.crmicr.2024.100245_bib0067","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.crmicr.2024.100245_bib0068","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.drup.2007.04.002","article-title":"Resistance to echinocandin-class antifungal drugs","volume":"10","author":"Perlin","year":"2007","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.crmicr.2024.100245_bib0069","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02429-19","article-title":"Combination therapy with ibrexafungerp (formerly SCY-078), a first-in-class triterpenoid inhibitor of (1\u2013>3)-beta-d-glucan synthesis, and isavuconazole for treatment of experimental invasive pulmonary aspergillosis","volume":"64","author":"Petraitis","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.crmicr.2024.100245_bib0070","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1128\/AAC.01588-12","article-title":"In vitro activity of a new oral glucan synthase inhibitor (MK-3118) tested against Aspergillus spp. by CLSI and EUCAST broth microdilution methods","volume":"57","author":"Pfaller","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.crmicr.2024.100245_bib0071","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00161-17","article-title":"Differential activity of the oral glucan synthase inhibitor SCY-078 against wild-type and echinocandin-resistant strains of Candida species","volume":"61","author":"Pfaller","year":"2017","journal-title":"Antimicrob. Agents Chemother"},{"key":"10.1016\/j.crmicr.2024.100245_bib0072","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.2174\/138945012803530107","article-title":"Analysis of current antifungal agents and their targets within the Pneumocystis carinii genome","volume":"13","author":"Porollo","year":"2012","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.crmicr.2024.100245_bib0073","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.906563","article-title":"In vitro antifungal activity of ibrexafungerp (SCY-078) against contemporary blood isolates from medically relevant species of Candida: a European study","volume":"12","author":"Quindos","year":"2022","journal-title":"Front. Cell Infect. Microbiol."},{"key":"10.1016\/j.crmicr.2024.100245_bib0074","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/mmy\/myx144","article-title":"Triazole resistance surveillance in Aspergillus fumigatus","volume":"56","author":"Resendiz Sharpe","year":"2018","journal-title":"Med. Mycol."},{"key":"10.1016\/j.crmicr.2024.100245_bib0075","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3390\/jof7030232","article-title":"In vitro activity of ibrexafungerp against a collection of clinical isolates of Aspergillus, including cryptic species and Cyp51A mutants, using EUCAST and CLSI methodologies","volume":"7","author":"Rivero-Menendez","year":"2021","journal-title":"J. Fungi (Basel)"},{"key":"10.1016\/j.crmicr.2024.100245_bib0076","doi-asserted-by":"crossref","first-page":"4174","DOI":"10.1128\/AAC.00917-07","article-title":"A Ser678Pro substitution in Fks1p confers resistance to echinocandin drugs in Aspergillus fumigatus","volume":"51","author":"Rocha","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.crmicr.2024.100245_bib0077","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01102-17","article-title":"Antifungal activity of SCY-078 and standard antifungal agents against 178 clinical isolates of resistant and susceptible Candida species","volume":"61","author":"Schell","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.crmicr.2024.100245_bib0078","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1093\/cid\/ciab750","article-title":"Ibrexafungerp versus placebo for vulvovaginal candidiasis treatment: a phase 3, randomized, controlled superiority trial (VANISH 303)","volume":"74","author":"Schwebke","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.crmicr.2024.100245_bib0079","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01961-16","article-title":"SCY-078 is fungicidal against Candida species in time-kill studies","volume":"61","author":"Scorneaux","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.crmicr.2024.100245_bib0080","unstructured":"SCYNEXIS, Inc. 2021. 'SCYNEXIS announces FDA approval of BREXAFEMME R (ibrexafungerp tablets) as the first and only oral non-azole treatment for vaginal yeast infections [media release].', Accessed November 10 2023. https:\/\/www.biospace.com\/article\/releases\/scynexis-announces-fda-approval-of-brexafemme-ibrexafungerp-tablets-as-the-first-and-only-oral-non-azole-treatment-for-vaginal-yeast-infections\/."},{"key":"10.1016\/j.crmicr.2024.100245_bib0081","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.idc.2021.03.001","article-title":"Recent trends in the epidemiology of fungal infections","volume":"35","author":"Seagle","year":"2021","journal-title":"Infect. Dis. Clin. North Am."},{"key":"10.1016\/j.crmicr.2024.100245_bib0082","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s12281-021-00419-5","article-title":"Investigational agents for the treatment of resistant yeasts and molds","volume":"15","author":"Seiler","year":"2021","journal-title":"Curr. Fungal Infect. Rep."},{"key":"10.1016\/j.crmicr.2024.100245_bib0083","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.drup.2014.06.001","article-title":"The role of azoles in the management of azole-resistant aspergillosis: from the bench to the bedside","volume":"17","author":"Seyedmousavi","year":"2014","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.crmicr.2024.100245_bib0084","series-title":"European Congress of Clinical Microbiology and Infectious Diseases","article-title":"Outcomes of oral ibrexafungerp in subjects with urinary tract infections from two phase 3 openlabel studies: difficult-to-treat invasive fungal infections (FURI) and infections with Candida auris (CARES)","author":"Siebert","year":"2023"},{"key":"10.1016\/j.crmicr.2024.100245_bib0085","series-title":"European Congress of Clinical Microbiology and Infectious Diseases","article-title":"Outcomes of oral ibrexafungerp in the treatment of 18 patients with Candida auris infections, from the CARES study","author":"Siebert","year":"2022"},{"key":"10.1016\/j.crmicr.2024.100245_bib0086","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1128\/AEM.00231-09","article-title":"Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles","volume":"75","author":"Snelders","year":"2009","journal-title":"Appl. Environ. Microbiol."},{"key":"10.1016\/j.crmicr.2024.100245_bib0087","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/S0140-6736(07)60917-9","article-title":"Vulvovaginal candidosis","volume":"369","author":"Sobel","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.crmicr.2024.100245_bib0088","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/1471-0528.16972","article-title":"Efficacy and safety of oral ibrexafungerp for the treatment of acute vulvovaginal candidiasis: a global phase 3, randomised, placebo-controlled superiority study (VANISH 306)","volume":"129","author":"Sobel","year":"2022","journal-title":"BJOG."},{"key":"10.1016\/j.crmicr.2024.100245_bib0089","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1093\/jac\/dkz277","article-title":"MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis","volume":"74","author":"Spec","year":"2019","journal-title":"J. Antimicrob. Chemother"},{"key":"10.1016\/j.crmicr.2024.100245_bib0090","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac492.064","article-title":"Oral ibrexafungerp outcomes by fungal disease in patients from an interim analysis of a phase 3 open-label study (FURI)","volume":"9","author":"Thompson","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.crmicr.2024.100245_bib0091","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1056\/NEJMra2027424","article-title":"Aspergillus infections","volume":"385","author":"Thompson","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.crmicr.2024.100245_bib0092","article-title":"Clinical characteristics and prognostic risk factors of patients with proven invasive pulmonary aspergillosis: a single-institution retrospective study","volume":"8","author":"Tong","year":"2021","journal-title":"Front. Med. (Lausanne)"},{"key":"10.1016\/j.crmicr.2024.100245_bib0093","series-title":"51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)","article-title":"A phase I multiple rising dose study evaluating safety, tolerability, and pharmacokinetics of MK-3118, oral glucan synthase inhibitor, in healthy volunteers","author":"Trucksis","year":"2011"},{"key":"10.1016\/j.crmicr.2024.100245_bib0094","series-title":"50th Interscience Conference on Antimicrobial Agents and Chemotherapy","article-title":"A phase I single rising dose study evaluating the safety, tolerability and pharmacokinetics of an oral glucan synthase inhibitor in healthy male volunteers","author":"Trucksis","year":"2010"},{"key":"10.1016\/j.crmicr.2024.100245_bib0095","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S1473-3099(09)70265-8","article-title":"Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use?","volume":"9","author":"Verweij","year":"2009","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.crmicr.2024.100245_bib0096","doi-asserted-by":"crossref","first-page":"5099","DOI":"10.1128\/AAC.00432-11","article-title":"Discovery of a novel class of orally active antifungal beta-1,3-D-glucan synthase inhibitors","volume":"55","author":"Walker","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.crmicr.2024.100245_bib0097","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/clinchem\/hvab217","article-title":"Emerging fungal infections: new species, new names, and antifungal resistance","volume":"68","author":"Wiederhold","year":"2021","journal-title":"Clin. Chem."},{"key":"10.1016\/j.crmicr.2024.100245_bib0098","doi-asserted-by":"crossref","first-page":"857","DOI":"10.3390\/jof8080857","article-title":"Pharmacodynamics, mechanisms of action and resistance, and spectrum of activity of new antifungal agents","volume":"8","author":"Wiederhold","year":"2022","journal-title":"J. Fungi (Basel)"},{"key":"10.1016\/j.crmicr.2024.100245_bib0099","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1093\/jac\/dkx422","article-title":"Oral glucan synthase inhibitor SCY-078 is effective in an experimental murine model of invasive candidiasis caused by WT and echinocandin-resistant Candida glabrata","volume":"73","author":"Wiederhold","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.crmicr.2024.100245_bib0100","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1086\/421946","article-title":"Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study","volume":"39","author":"Wisplinghoff","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.crmicr.2024.100245_bib0101","unstructured":"World Health Organization. 2022. 'WHO releases first-ever list of health-threatening fungi', Accessed November 10 2023. https:\/\/www.who.int\/news\/item\/25-10-2022-who-releases-first-ever-list-of-health-threatening-fungi."},{"key":"10.1016\/j.crmicr.2024.100245_bib0102","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02119-18","article-title":"SCY-078, a novel fungicidal agent, demonstrates distribution to tissues associated with fungal infections during mass balance studies with intravenous and oral [(14)C]SCY-078 in albino and pigmented rats","volume":"63","author":"Wring","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.crmicr.2024.100245_bib0103","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1002\/jcph.1146","article-title":"Lack of impact by SCY-078, a first-in-class oral fungicidal glucan synthase inhibitor, on the pharmacokinetics of rosiglitazone, a substrate for CYP450 2C8, supports the low risk for clinically relevant metabolic drug-drug interactions","volume":"58","author":"Wring","year":"2018","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.crmicr.2024.100245_bib0104","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/cpdd.588","article-title":"Clinical pharmacokinetics and drug-drug interaction potential for coadministered SCY-078, an oral fungicidal glucan synthase inhibitor, and tacrolimus","volume":"8","author":"Wring","year":"2019","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.crmicr.2024.100245_bib0105","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02068-16","article-title":"Preclinical pharmacokinetics and pharmacodynamic target of SCY-078, a first-in-class orally active antifungal glucan synthesis inhibitor, in murine models of disseminated candidiasis","volume":"61","author":"Wring","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.crmicr.2024.100245_bib0106","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105922","article-title":"Pan-resistant Candida auris isolates from the outbreak in New York are susceptible to ibrexafungerp (a glucan synthase inhibitor)","volume":"55","author":"Zhu","year":"2020","journal-title":"Int. J. Antimicrob. Agents"}],"container-title":["Current Research in Microbial Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666517424000270?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666517424000270?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T18:11:35Z","timestamp":1718647895000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666517424000270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":107,"alternative-id":["S2666517424000270"],"URL":"https:\/\/doi.org\/10.1016\/j.crmicr.2024.100245","relation":{},"ISSN":["2666-5174"],"issn-type":[{"value":"2666-5174","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ibrexafungerp: A narrative overview","name":"articletitle","label":"Article Title"},{"value":"Current Research in Microbial Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.crmicr.2024.100245","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100245"}}